Akebia Therapeutics Inc. (AKBA) concluded trading on Thursday at a closing price of $1.27, with 4.87 million shares of worth about $6.18 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -18.59% during that period and on July 11, 2024 the price saw a gain of about 17.59%. Currently the company’s common shares owned by public are about 194.58M shares, out of which, 191.52M shares are available for trading.
Stock saw a price change of 34.18% in past 5 days and over the past one month there was a price change of 16.51%. Year-to-date (YTD), AKBA shares are showing a performance of 2.42% which increased to 10.43% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.78 but also hit the highest price of $2.48 during that period. The average intraday trading volume for Akebia Therapeutics Inc. shares is 3.24 million. The stock is currently trading 27.60% above its 20-day simple moving average (SMA20), while that difference is up 14.05% for SMA50 and it goes to 0.25% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Akebia Therapeutics Inc. (NASDAQ: AKBA) currently have 194.58M outstanding shares and institutions hold larger chunk of about 20.89% of that.
The stock has a current market capitalization of $266.19M and its 3Y-monthly beta is at 0.77. It has posted earnings per share of -$0.22 in the same period. It has Quick Ratio of 1.31. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AKBA, volatility over the week remained 9.40% while standing at 8.47% over the month.
Stock’s fiscal year EPS is expected to rise by 7.02% while it is estimated to increase by 22.89% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BTIG Research on November 29, 2023 offering a Buy rating for the stock and assigned a target price of $4 to it. Coverage by H.C. Wainwright stated Akebia Therapeutics Inc. (AKBA) stock as a Buy in their note to investors on August 28, 2023, suggesting a price target of $3.75 for the stock. On May 31, 2023, Piper Sandler Upgrade their recommendations, while on March 31, 2022, Piper Sandler Downgrade their ratings for the stock with a price target of $2. Stock get a Hold rating from Needham on March 31, 2022.
